Abivax (AAVXF) Cash from Financing Activities (2024 - 2026)

Abivax has reported Cash from Financing Activities for 3 years, with the latest figure at $85464.4 in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 101.04% year-over-year to $85464.4 in Q1 2026; TTM through Mar 2026 was $637.1 billion, a 2015.85% increase from a year earlier, with the FY2025 full-year figure at $637.1 billion, up 2013.64% from the prior year.
• Cash from Financing Activities was $85464.4 for Q1 2026 at Abivax, down from $636.4 billion in the prior quarter.
• The five-year high for Cash from Financing Activities was $636.4 billion in Q4 2025, with the low at -$9.9 million in Q2 2025.
• Average Cash from Financing Activities over 3 years is $74.1 billion, with a median of $20.6 million recorded in 2024.
• The largest YoY upside for Cash from Financing Activities was 10314.41% in 2025 against a maximum downside of 148.19% in 2025.
• Over 3 years, Cash from Financing Activities stood at $30.1 billion in 2024, then surged by 2013.92% to $636.4 billion in 2025, then slumped by 100.0% to $85464.4 in 2026.
• The last three Cash from Financing Activities figures came in at $85464.4 (Q1 2026), $636.4 billion (Q4 2025), and $705.5 million (Q3 2025), per Business Quant data.